Negative symptoms of schizophrenia are improved by the addition of paroxetine to neuroleptics: A double-blind placebo-controlled study

Efficacy and safety of antidepressant augmentation of continued antipsychotic treatment in patients with schizophrenia

“…Altogether, 42 studies ( n = 1934) were included . About 40.5% of the studies focused on negative symptoms, 28.6% on total symptoms, 23.8% on depressive symptoms, and 7.1% on cognition.…”

Meta-Analysis of the Efficacy of Adjunctive NMDA Receptor Modulators in Chronic Schizophrenia

“…[69,70] Antidepressants have been used as an add-on therapy to antipsychotics with some success. [71][72][73] The use of other adjunctive agents, including NMDARMs, may have potential if they are found to yield a clinically appreciable improvement in symptoms of schizophrenia. In clinical trials, agents such as D-alanine, D-cycloserine, D-serine, glycine and sarcosine have been used as adjunct therapy to antipsychotics for the treatment of schizophrenia.…”

Combination Therapy in the Treatment of Schizophrenia

“…There is one study of augmentation with citalopram [65] and one with sertraline [41] , which showed no advantages in the management of negative symptoms over placebo. On the other hand, the combination with paroxetine improved negative symptoms (PANSS negative subscore), without aff ecting depressivity (Hamilton Depression Scale, HAMD) [32] . Positive results were also obtained from two studies of cotreatment with mirtazapine, which signifi cantly improved negative, together with general psychopathology symptoms [6,75] .…”